Oralogik - A New Approach to Complex Oral Drug Delivery Profiles
BDD has developed an erosion based controlled release technology that provides unrivalled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. The barrier layer is designed to erode at a controlled rate until eventually the drug is released from the core tablet, and the length of the delay period can be tailored between 2 and 8 hours by simply changing excipient ratios.
The barrier layer works independently of the core so can be applied to almost any drug where there is a therapeutic need, with minimal development. The release can be sustained or pulsed release giving unparalleled versatility.
The OralogiK barrier layer can be readily film coated, allowing addition of an immediate release dose which can be the same or different to the drug in the core tablet
BDD Pharma Ltd
-
GB
-
2016On CPHI since
-
50 - 99Employees
Other Content from BDD Pharma Ltd ()
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance